Shopping Cart
Remove All
Your shopping cart is currently empty
Azintuxizumab
Catalog No. T82927 Copy Product Info
Purity: 95%
🥰Excellent
Azintuxizumab, an IgG4 bispecific antibody, is designed to specifically recognize and bind to the B-cell maturation antigen (BCMA), a molecular marker associated with plasma cell malignancies. Azintuxizumab shows significant promise in preclinical and translational research investigating therapeutic interventions for relapsed or refractory multiple myeloma (RRMM), thereby providing a dual-targeted mechanism of action for antibody-based immunotherapy.
Azintuxizumab
Copy Product Info🥰Excellent
Catalog No. T82927
Azintuxizumab, an IgG4 bispecific antibody, is designed to specifically recognize and bind to the B-cell maturation antigen (BCMA), a molecular marker associated with plasma cell malignancies. Azintuxizumab shows significant promise in preclinical and translational research investigating therapeutic interventions for relapsed or refractory multiple myeloma (RRMM), thereby providing a dual-targeted mechanism of action for antibody-based immunotherapy.
Azintuxizumab
Cas No. 1826819-57-1
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | - | In Stock | |
| 5 mg | $747 | - | In Stock | |
| 10 mg | $1,200 | - | In Stock | |
| 25 mg | $1,770 | - | In Stock | |
| 50 mg | $2,380 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:98.3% (SDS-PAGE); 96.8% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Azintuxizumab, an IgG4 bispecific antibody, is designed to specifically recognize and bind to the B-cell maturation antigen (BCMA), a molecular marker associated with plasma cell malignancies. Azintuxizumab shows significant promise in preclinical and translational research investigating therapeutic interventions for relapsed or refractory multiple myeloma (RRMM), thereby providing a dual-targeted mechanism of action for antibody-based immunotherapy. |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | SLAMF7/CS1 |
| Molecular Weight | 146.04 kDa |
| Cas No. | 1826819-57-1 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Keywords
Preview
Related Tags: buy Azintuxizumab | purchase Azintuxizumab | Azintuxizumab cost | order Azintuxizumab | Azintuxizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.